Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry
<p>Abstract</p> <p>Background</p> <p>Gastrointestinal stromal tumors (GIST), one of the most common mesenchymal tumors of the gastrointestinal tract, prior to routine immunohistochemical staining and the introduction of tyrosine kinase inhibitors, were often mistaken fo...
Main Authors: | Call Jerry, Walentas Christopher D, Eickhoff Jens C, Scherzer Norman |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-03-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/12/90 |
Similar Items
-
Mechanisms of the resistance of gastrointestinal stromal tumors to imatinib
by: A R Galembikova, et al.
Published: (2018-12-01) -
Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective
by: Ward Jeremy B, et al.
Published: (2008-07-01) -
Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease
by: Rebecca M. Platoff, et al.
Published: (2017-01-01) -
Update on imatinib for gastrointestinal stromal tumors: duration of treatment
by: Linch M, et al.
Published: (2013-07-01) -
Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
by: Omar S Din, et al.
Published: (2008-03-01)